ANIP(ANI Pharmaceuticals, Inc.) · 财务报表

ANIP(ANI Pharmaceuticals, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$216.14M$316.38M$486.82M$614.38M$883.37M
毛利润—————
营业利润−$39.79M−$35.28M$46.97M$584.00K$111.09M
净利润−$42.60M−$47.90M$18.78M−$18.52M$78.34M
经营现金流$3.32M−$31.20M$118.96M$64.02M$185.22M
自由现金流$765.00K−$40.08M$110.09M$47.78M$171.39M
摊薄每股收益$-3.40$-3.05$0.85$-1.04$3.32

ANI Pharmaceuticals, Inc. ANIP